

What is claimed is

1. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can selectively kill  
5 Fusobacterium varium cells.
2. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can neutralize the toxin produced by Fusobacterium varium cells.
3. A pharmaceutical composition of treatment for a patient with  
10 ulcerative colitis comprising a drug which can inhibit the adhesion of Fusobacterium varium cells to the intestinal mucosa.
4. A pharmaceutical composition of treatment for a patient with ulcerative colitis comprising a drug which can inhibit the invasion of Fusobacterium varium cells into the intestinal mucosa.
- 15 5. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 1.
6. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 2.
7. A vaccine for preventing ulcerative colitis from infection with  
20 Fusobacterium varium comprising a drug as set forth in claim 3.
8. A vaccine for preventing ulcerative colitis from infection with Fusobacterium varium comprising a drug as set forth in claim 4.
9. A method for screening a drug for selectively killing Fusobacterium varium cells comprising the step of administering a drug to be examined  
25 to an experimental model of Fusobacterium varium-infection to thus select a drug, which can selectively kill the bacterium.
10. A method for screening a therapeutic agent for ulcerative colitis comprising the step of administering a candidate drug which selectively

kills the bacterium in a patient with ulcerative colitis and positive to *Fusobacterium varium* to thus select a drug capable of improving the symptoms of the patients suffering from the disease.

11. An animal as a model of ulcerative colitis obtained by administering  
5 a toxin produced by *Fusobacterium varium* to an animal.
12. The animal model of ulcerative colitis as set forth in claim 11,  
wherein the toxin is butyric acid.
13. An animal as a model for ulcerative colitis comprising living  
*Fusobacterium varium* cells adhered to the mucosa.
- 10 14. A method for making a diagnosis of ulcerative colitis comprising the  
step of detecting an antibody against *Fusobacterium varium*.
15. An agent for making a diagnosis of ulcerative colitis comprising an  
antibody against *Fusobacterium varium*, which has the highest detection  
sensitivity and the highest specificity.

15